Study of the excess cost associated with the drug wasted due to limited options of the size of anti-cancer drug vials, among patients receiving such treatment at Tata Memorial Hospital
- Conditions
- Health Condition 1: C00-D49- Neoplasms
- Registration Number
- CTRI/2020/08/027054
- Lead Sponsor
- ot Applicable
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Adult cancer patients
The patients advised and receiving any of the following 62 chemotherapy protocols will be included in the study.
Solid 1
AC
Paclitaxel+-trastuzumab
Gemcitabine+carboplatin
EC
TDM1
CMF
Carboplatin+paclitaxel+/-Bevacizumab
Liposomal doxorubin
TCH(Docetaxel,carboplatin,trastuzumab)
BEP
EP
EMACO
EMA EP
SA Dactinomycin
SA Methotrexate
mFOLFOX
FOLFIRI
Cape-OX
Cap-Irinotecan
SA Docetaxel
Cetuximab
Panitumumab
Trastuzumab
Ramucirumab
Cape-Mitomycin
FOLFIRINOX
Gem-Oxaliplatin
Gem+cisplatin
DOF
EOX
DCF
Gem+nab paclitaxel
Solid 2
Pemetrexed+Cisplatin
Pemetrexed+Carboplatin
Pemetrexed-carboplatin+/- pembrolizumab
Gemcitabine+carboplatin
Paclitaxel+carboplatin
Geftinib+bevacizumab
Nivolumab
Cisplatin+etoposide
Carboplatin+etoposide
SA Irinotecan
SA Gemcitabine
SA Paclitaxel
SA Docetaxel
BEP
EP
Gemcitabine+cisplatin
Gemcitabine+carboplatin
TIP
Adult Hematology
VCD
VRD
RDHAP
RGDP
RCHOP
ABVD
Bendamustine-rituximab
FCR
R EPOCH
HiDAC
CHOP
RCEOP
patients aged < 18 years
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method